Weekly shot could replace daily HIV pills for some patients
NCT ID NCT02859961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a weekly injection of PRO 140 (Leronlimab) could keep HIV under control in people whose virus was already suppressed by daily pills. Over 500 participants switched from their regular medication to the shot alone for 48 weeks. The goal was to see how many could maintain viral suppression without their virus rebounding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO 140 (Leronlimab) injection
What this could lead to
If successful, this could offer a simpler, long-acting maintenance option for people with HIV, reducing the need for daily pills.
What could go wrong
This is an early-to-mid stage trial with a moderate number of participants. The treatment may not work for everyone, and some patients experienced virologic failure. Long-term safety and effectiveness are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD03 Investigational site
La Mesa, California, 91942, United States
-
CD03 Investigational site
Palm Springs, California, 92262, United States
-
CD03 Investigational site
San Francisco, California, 94115, United States
-
CD03 Investigational site
New Haven, Connecticut, 06510, United States
-
CD03 Investigational site
Norwalk, Connecticut, 06850, United States
-
CD03 Investigational site
Ft. Pierce, Florida, 34982, United States
-
CD03 Investigational site
Orlando, Florida, 32803, United States
-
CD03 Investigational site
West Palm Beach, Florida, 33401, United States
-
CD03 Investigational site
Wichita, Kansas, 67214, United States
-
CD03 Investigational site
Las Vegas, Nevada, 89109, United States
-
CD03 Investigational site
New York, New York, 10011, United States
-
CD03 Investigational site
Syracuse, New York, 13210, United States